Preventive effect of hydrolyzed infant formulas persists until age 6:: long-term results from the German Infant Nutritional Intervention Study GINI, a randomised, double-blind trial

被引：0
|
作者：
von Berg, A. [1 ]
Filipiak-Pittroff, B. [1 ]
Kraemer, U. [1 ]
Link, E. [1 ]
Bollrath, C. [1 ]
Brockow, I [1 ]
Koletzko, S. [1 ]
Gruebl, A. [1 ]
Heinrich, J. [1 ]
Wichmann, H. [1 ]
Bauer, C. [1 ]
Reinhardt, D. [1 ]
Berdel, D. [1 ]
机构：
[1] Marien Hosp Wesel, Childrens Dept, Wesel, Germany
来源：
ALLERGY | 2008年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
114
引用
收藏
页码：53 / 54
页数：2
相关论文
共 29 条
  • [21] LONG-TERM SAFETY OF ADJUNCTIVE ONCE-DAILY ZONISAMIDE IN PAEDIATRIC PATIENTS WITH PARTIAL EPILEPSY: RESULTS OF AN OPEN-LABEL EXTENSION STUDY OF A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Guerrini, R.
    Bagul, M.
    Rosati, A.
    Bradshaw, K.
    Giorgi, L.
    EPILEPSIA, 2013, 54 : 174 - 174
  • [22] Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial (vol 1, pg 610, 2013)
    Valery, P. C.
    Morris, P. S.
    Byrnes, C. A.
    LANCET RESPIRATORY MEDICINE, 2015, 3 (08): : E29 - E29
  • [24] Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, 3 trial
    Ogbuagu, Onyema
    Ruane, Peter J.
    Podzamczer, Daniel
    Salazar, Laura C.
    Henry, Keith
    Asmuth, David M.
    Wohl, David
    Gilson, Richard
    Shao, Yongwu
    Ebrahimi, Ramin
    Cox, Stephanie
    Kintu, Alexander
    Carter, Christoph
    Das, Moupali
    Baeten, Jared M.
    Brainard, Diana M.
    Whitlock, Gary
    Brunetta, Jason M.
    Kronborg, Gitte
    Spinner, Christoph D.
    LANCET HIV, 2021, 8 (07): : E397 - E407
  • [25] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    Buehrer, Emanuel
    Kicinski, Michal
    Mandala, Mario
    Pe, Madeline
    Long, Georgina, V
    Atkinson, Victoria
    Blank, Christian U.
    Haydon, Andrew
    Dalle, Stephane
    Khattak, Adnan
    Carlino, Matteo S.
    Meshcheryakov, Andrey
    Sandhu, Shahneen
    Puig, Susana
    Schadendorf, Dirk
    Jamal, Rahima
    Rutkowski, Piotr
    van den Eertwegh, Alfonsus J. M.
    Coens, Corneel
    Grebennik, Dmitri
    Krepler, Clemens
    Robert, Caroline
    Eggermont, Alexander
    LANCET ONCOLOGY, 2024, 25 (09): : 1202 - 1212
  • [26] A comparison of full-analysis and per-protocol data sets for assessment of the long-term efficacy of bifeprunox in patients with stable schizophrenia: Results from a 6-month randomized, double-blind, placebo-controlled study
    Bourin, Michel
    Casey, Daniel E.
    Debelle, Marc
    Heisterberg, Jens
    Josiassen, Mette Krog
    Ostergard, Jette Buch
    Shapira, Nathan A.
    Yeung, Paul P.
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 79S - 79S
  • [27] Long-term efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: results from a 52-week randomized, double-blind, placebo-controlled multicentre trial
    Dogra, S.
    Krupashankar, D. S.
    Naidu, P.
    Prasanna, C. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 5 - 5
  • [28] Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg e397, 2021)
    Ogbuagu, O.
    Ruane, P. J.
    Podzamczer, D.
    LANCET HIV, 2021, 8 (12): : E734 - E734
  • [29] Long-term safety and immunogenicity of an MF59- adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or >56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
    Chappell, Keith J.
    Mordant, Francesca L.
    Amarilla, Alberto A.
    Modhiran, Naphak
    Liang, Benjamin
    Li, Zheyi
    Wijesundara, Danushka K.
    Lackenby, Julia A.
    Grif, Paul
    Bennet, Jillian K.
    Hensen, Luca
    Zhang, Wuji
    Nguyen, Thi H. O.
    Tran, Mai H.
    Tapley, Peter
    Barnes, James
    Reading, Patrick C.
    Kedzierska, Katherine
    Ranasinghe, Charani
    Subbarao, Kanta
    Watterson, Daniel
    Young, Paul R.
    Munro, Trent P.
    EBIOMEDICINE, 2023, 97
123